Elevation Oncology Analyst Ratings
Elevation Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/29/2023 | 121.89% | HC Wainwright & Co. | → $1.5 | Initiates Coverage On | → Buy |
| 06/05/2023 | 787.57% | Wedbush | $4 → $6 | Maintains | Outperform |
| 05/30/2023 | 1083.43% | SVB Securities | $5 → $8 | Upgrades | Market Perform → Outperform |
| 03/10/2023 | 491.72% | Wedbush | → $4 | Reiterates | → Outperform |
| 01/09/2023 | 47.93% | SVB Leerink | $2 → $1 | Maintains | Market Perform |
| 11/10/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/07/2022 | 195.86% | SVB Leerink | $11 → $2 | Downgrades | Outperform → Market Perform |
| 09/19/2022 | 1009.47% | HC Wainwright & Co. | → $7.5 | Assumes | → Buy |
| 08/08/2022 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 03/04/2022 | 3006.51% | Wedbush | $27 → $21 | Maintains | Outperform |
| 12/23/2021 | 1675.15% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 07/20/2021 | 3894.08% | Wedbush | → $27 | Initiates Coverage On | → Outperform |
| 07/20/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/20/2021 | 2858.58% | SVB Leerink | → $20 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/29/2023 | 121.89% | HC Wainwright公司 | →$1.5 | 开始承保 | →购买 |
| 06/05/2023 | 787.57% | 韦德布什 | $4→$6 | 维护 | 跑赢大盘 |
| 2023年05月30日 | 1083.43% | SVB证券 | $5→$8 | 升级 | 市场表现优于→ |
| 03/10/2023 | 491.72% | 韦德布什 | →$4 | 重申 | →跑赢大盘 |
| 01/09/2023 | 47.93% | SVB Leerink | $2→$1 | 维护 | 市场表现 |
| 2022年11月10日 | - | 摩根大通 | 评级下调 | 中性→减持 | |
| 11/07/2022 | 195.86% | SVB Leerink | $11→$2 | 评级下调 | 跑赢→市场表现 |
| 2022/09/19 | 1009.47% | HC Wainwright公司 | →$7.5 | 假设 | →购买 |
| 2022/08/08 | - | 摩根大通 | 评级下调 | 超重→中性 | |
| 03/04/2022 | 3006.51% | 韦德布什 | $27→$21 | 维护 | 跑赢大盘 |
| 2021年12月23日 | 1675.15% | HC Wainwright公司 | →$12 | 开始承保 | →购买 |
| 07/20/2021 | 3894.08% | 韦德布什 | →$27 | 开始承保 | →跑赢大盘 |
| 07/20/2021 | - | 考恩公司 | 开始承保 | →跑赢大盘 | |
| 07/20/2021 | 2858.58% | SVB Leerink | →$20 | 开始承保 | →跑赢大盘 |
What is the target price for Elevation Oncology (ELEV)?
Elevation Oncology(ELEV)的目标价格是多少？
The latest price target for Elevation Oncology (NASDAQ: ELEV) was reported by HC Wainwright & Co. on September 29, 2023. The analyst firm set a price target for $1.50 expecting ELEV to rise to within 12 months (a possible 121.89% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright&Co.于2023年9月29日报道了Elevation Oncology(纳斯达克：ELEV)的最新目标价。这家分析公司将目标价定为1.5美元，预计Elev将在12个月内上涨(可能上涨121.89)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Elevation Oncology (ELEV)?
Elevation Oncology(ELEV)的最新分析师评级是多少？
The latest analyst rating for Elevation Oncology (NASDAQ: ELEV) was provided by HC Wainwright & Co., and Elevation Oncology initiated their buy rating.
高地肿瘤学公司(纳斯达克代码：ELEV)的最新分析师评级由HC Wainwright&Co.提供，高地肿瘤学公司启动了他们的买入评级。
When is the next analyst rating going to be posted or updated for Elevation Oncology (ELEV)?
Elevation Oncology(ELEV)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elevation Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elevation Oncology was filed on September 29, 2023 so you should expect the next rating to be made available sometime around September 29, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Elevation Oncology的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Elevation Oncology的上一次评级是在2023年9月29日提交的，所以你应该预计下一次评级将在2024年9月29日左右提供。
Is the Analyst Rating Elevation Oncology (ELEV) correct?
分析师评级提升肿瘤学(ELEV)正确吗？
While ratings are subjective and will change, the latest Elevation Oncology (ELEV) rating was a initiated with a price target of $0.00 to $1.50. The current price Elevation Oncology (ELEV) is trading at is $0.68, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的海拔肿瘤学(ELEV)评级是以0.00美元至1.50美元的目标价启动的。目前ELEV的价格为0.68美元，在分析师的预测范围内。